NICE Update Doubles Eligible Patients for AZ's Lokelma

Why It Matters

Expanding Lokelma’s eligibility enables earlier potassium control, preserving life‑saving RAAS inhibitor therapy and reducing costly hospitalisations. The move also illustrates how higher cost‑effectiveness thresholds can unlock market growth for innovative mid‑tier drugs.

Key Takeaways

• NICE draft doubles eligible Lokelma patients in England and Wales
• Potassium threshold lowered from 6.0 to 5.5 mmol/L
• Specialist‑only initiation restriction removed, primary care can prescribe
• Cost‑effectiveness ceiling raised to £25k‑£35k (~$31k‑$44k) per QALY
• Lokelma sales rose 28% to $698 million, targeting $1 billion

Pulse Analysis

The National Institute for Health and Care Excellence (NICE) has lifted its cost‑effectiveness ceiling from the historic £20,000‑£30,000 range to roughly £25,000‑£35,000 per quality‑adjusted life year (about $31,000‑$44,000). This adjustment reflects mounting pressure that older thresholds no longer capture the value of innovative therapies. By applying the higher ceiling to AstraZeneca’s sodium zirconium cyclosilicate, Lokelma, NICE signals a willingness to fund medicines that deliver measurable clinical benefits even when priced above legacy limits, paving the way for broader NHS adoption.

The draft guidance also expands the eligible patient pool by lowering the serum potassium trigger from 6.0 mmol/L to 5.5 mmol/L and removing the requirement that only specialists can start treatment. Clinicians can now intervene earlier, preventing the abrupt discontinuation or dose reduction of renin‑angiotensin‑aldosterone system inhibitors that are essential for managing chronic kidney disease and heart failure. Early potassium control is linked to fewer hospitalisations, lower cardiovascular event rates, and improved survival, offering a proactive tool for primary‑care teams.

For AstraZeneca, the policy shift translates into a commercial upside. Lokelma’s 2023 revenue jumped 28% to $698 million, outpacing rival CSL’s Veltassa, and the company forecasts breaching the $1 billion blockbuster milestone. The expanded indication not only widens the addressable market in England and Wales but also sets a precedent for other mid‑tier drugs to leverage real‑world evidence in reimbursement negotiations. As the UK market embraces higher thresholds, pharmaceutical firms are likely to prioritize data‑driven dossiers to secure faster, wider patient access.